MMHD:TASEMenora Mivtachim Holdings Ltd. Analysis
Data as of 2026-06-12 - not real-time
ILA 48,710.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
The stock is trading well above its 20‑day and 50‑day moving averages, confirming a short‑term bullish bias. Momentum indicators show a mid‑range RSI, suggesting neither overbought nor oversold conditions. However, the MACD line remains below the signal line with a negative histogram, hinting at underlying bearish pressure. Volume has been increasing, reinforcing the current trend direction that technical models label as bullish. The price sits comfortably above the identified support level but still has room to climb toward the resistance zone. Volatility over the past month is elevated, yet the beta is markedly low, indicating the stock moves less than the broader market.
Fundamentally, the P/E ratio sits below the industry average, while the dividend yield remains attractive with a modest payout ratio. The DCF model values the company substantially higher than the market price, pointing to a clear undervaluation gap. Revenue growth is solid and margins are healthy, supporting a resilient earnings profile. Return on equity is strong, cash balances are ample, and debt levels are manageable, underpinning dividend sustainability. The fear‑and‑greed index is in the “Extreme Greed” zone, reflecting strong investor sentiment that could boost short‑term buying pressure. Overall, the combination of technical strength, attractive valuation, and stable fundamentals makes the stock a compelling candidate for investors with a value‑oriented outlook.
Fundamentally, the P/E ratio sits below the industry average, while the dividend yield remains attractive with a modest payout ratio. The DCF model values the company substantially higher than the market price, pointing to a clear undervaluation gap. Revenue growth is solid and margins are healthy, supporting a resilient earnings profile. Return on equity is strong, cash balances are ample, and debt levels are manageable, underpinning dividend sustainability. The fear‑and‑greed index is in the “Extreme Greed” zone, reflecting strong investor sentiment that could boost short‑term buying pressure. Overall, the combination of technical strength, attractive valuation, and stable fundamentals makes the stock a compelling candidate for investors with a value‑oriented outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical bullish bias from moving averages
- MACD bearish divergence indicating caution
- Price approaching resistance level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF undervaluation suggests upside
- Strong ROE and low payout support earnings growth
- Increasing volume confirms buying interest
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust cash position and low leverage
- Sustainable dividend yield
- Low beta and defensive insurance sector
Key Metrics & Analysis
Financial Health
Revenue Growth12.30%
Profit Margin23.22%
P/E Ratio12.6
ROE28.75%
ROA3.14%
Debt/Equity66.31
P/B Ratio3.3
Op. Cash FlowILA1.4B
Free Cash FlowILA-17129963520
Industry P/E16.6
Technical Analysis
TrendBullish
RSI42.9
SupportILA 46,650.00
ResistanceILA 57,050.00
MA 20ILA 51,566.00
MA 50ILA 50,612.80
MA 200ILA 41,390.50
MACDBearish
VolumeIncreasing
Fear & Greed Index86.71
Valuation
Fair ValueILA 60,148.01
GradeUndervalued
TypeValue
Dividend Yield3.21%
Risk Assessment
Beta0.29
Volatility45.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.